Literature DB >> 21098695

Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker.

Véronique Hofman1, Christelle Bonnetaud, Marius I Ilie, Philippe Vielh, Jean Michel Vignaud, Jean François Fléjou, Sylvie Lantuejoul, Eric Piaton, Nadine Mourad, Catherine Butori, Eric Selva, Michel Poudenx, Stéphanie Sibon, Sabrina Kelhef, Nicolas Vénissac, Jean-Philippe Jais, Jérôme Mouroux, Thierry Jo Molina, Paul Hofman.   

Abstract

PURPOSE: Pathologic TNM staging is currently the best prognostic factor for non-small cell lung carcinoma (NSCLC). However, even in early-stage NSCLC, the recurrence rates after surgery range from 25% to 50%. The preoperative detection of circulating tumor cells (CTC) could be useful to tailor new therapeutic strategies in NSCLC. We assessed the presence of CTC in NSCLC patients undergoing surgery, using cytologic analyses, after their isolation by size of epithelial tumor cells (ISET method). The presence and the number of CTCs were considered and correlated with clinicopathologic parameters including patient follow-up. EXPERIMENTAL
DESIGN: Of the 247 blood samples tested, 208 samples were from patients with resectable NSCLC and 39 from healthy subjects. The mean follow-up was 24 months. An image of detected cells with presumably nonhematologic features [initially defined as "circulating nonhematologic cells" (CNHC)] was recorded. The presence of CNHC was assessed blindly and independently by 10 cytopathologists, using cytologic criteria of malignancy on stained filters. The count of detected CNHCs was made for each filter.
RESULTS: One hundred two of 208 (49%) patients showed CNHCs corresponding to CNHC with malignant cytopathologic features in 76 of 208 (36%) cases. CNHCs were not detected in the control group. A level of 50 or more CNHCs corresponding to the third quartile was associated with shorter overall and disease-free-survival, independently of disease staging, and with a high risk of recurrence and death in early-stage I + II-resectable NSCLC.
CONCLUSION: A high percentage of NSCLC patients show preoperative detection of CNHC by the ISET method. The presence and level of 50 or more CNHCs are associated with worse survival of patients with resectable NSCLC. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098695     DOI: 10.1158/1078-0432.CCR-10-0445

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  122 in total

1.  Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.

Authors:  Marco Wendel; Lyudmila Bazhenova; Rogier Boshuizen; Anand Kolatkar; Meghana Honnatti; Edward H Cho; Dena Marrinucci; Ajay Sandhu; Anthony Perricone; Patricia Thistlethwaite; Kelly Bethel; Jorge Nieva; Michel van den Heuvel; Peter Kuhn
Journal:  Phys Biol       Date:  2012-02-03       Impact factor: 2.583

Review 2.  Clinical utility of circulating tumour cell detection in non-small-cell lung cancer.

Authors:  Alberto Fusi; Robert Metcalf; Matthew Krebs; Caroline Dive; Fiona Blackhall
Journal:  Curr Treat Options Oncol       Date:  2013-12

3.  Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer.

Authors:  Anders Carlsson; Viswam S Nair; Madelyn S Luttgen; Khun Visith Keu; George Horng; Minal Vasanawala; Anand Kolatkar; Mehran Jamali; Andrei H Iagaru; Ware Kuschner; Billy W Loo; Joseph B Shrager; Kelly Bethel; Carl K Hoh; Lyudmila Bazhenova; Jorge Nieva; Peter Kuhn; Sanjiv S Gambhir
Journal:  J Thorac Oncol       Date:  2014-08       Impact factor: 15.609

4.  Inertia based microfluidic capture and characterisation of circulating tumour cells for the diagnosis of lung cancer.

Authors:  Dimple Y Chudasama; Daria V Freydina; Maxim B Freidin; Maria Leung; Angeles Montero Fernandez; Alexandra Rice; Andrew G Nicholson; Emmanouil Karteris; Vladimir Anikin; Eric Lim
Journal:  Ann Transl Med       Date:  2016-12

Review 5.  Circulating tumor cell enrichment based on physical properties.

Authors:  Ramdane A Harouaka; Merisa Nisic; Si-Yang Zheng
Journal:  J Lab Autom       Date:  2013-07-05

6.  Bridging population and tissue scale tumor dynamics: a new paradigm for understanding differences in tumor growth and metastatic disease.

Authors:  Sylvia Plevritis; Alexander R A Anderson; Jill Gallaher; Aravind Babu
Journal:  Cancer Res       Date:  2014-01-09       Impact factor: 12.701

Review 7.  CTC enumeration and characterization: moving toward personalized medicine.

Authors:  Angela Toss; Zhaomei Mu; Sandra Fernandez; Massimo Cristofanilli
Journal:  Ann Transl Med       Date:  2014-11

Review 8.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

Authors:  Marius Ilie; Véronique Hofman; Elodie Long; Olivier Bordone; Eric Selva; Kevin Washetine; Charles Hugo Marquette; Paul Hofman
Journal:  Ann Transl Med       Date:  2014-11

9.  Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood?

Authors:  Noriyoshi Sawabata; Soichiro Funaki; Takeru Hyakutake; Yasushi Shintani; Ayako Fujiwara; Meinoshin Okumura
Journal:  Surg Today       Date:  2016-03-07       Impact factor: 2.549

Review 10.  Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.

Authors:  Sumitra Mohan; Francesca Chemi; Ged Brady
Journal:  Transl Lung Cancer Res       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.